Empros Pharma
Privately held: no public share price · Sweden
Assets
(1 total)
1Total Assets
0Approved
0Phase 3 / Filed
1Phase 1–2 / Early
1Diseases
| Target & Modality | |||
|---|---|---|---|
| Phase 2 | GI lipase + intestinal alpha-glucosidaseSmall molecule | Obesity |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
3 November 2025Topline resultOrlistat/acarbose (EMP16)Phase 2 POEM study of EMP16 (NCT06993428): positive topline results
Financial reports
No financial reports recorded.